Zabopegdutide shows 63% MASH resolution in Phase 2 trial
D&D Pharmatech presented final 48-week Phase 2 liver biopsy data for Zabopegdutide at the AASLD meeting in November 2026. According to the company, the treated group achieved 62.5% MASH resolution without worsening fibrosis versus 5.3% for placebo (p<0.001), 50.0% fibrosis improvement withou
<p>D&D Pharmatech presented final 48-week Phase 2 liver biopsy data for Zabopegdutide at the AASLD meeting in November 2026. According to the company, the treated group achieved 62.5% MASH resolution without worsening fibrosis versus 5.3% for placebo (p<0.001), 50.0% fibrosis improvement withou</p>